Candel Therapeutics, Inc. (CADL)
- Previous Close
8.90 - Open
8.99 - Bid 8.33 x 200
- Ask 8.39 x 200
- Day's Range
8.14 - 9.05 - 52 Week Range
0.66 - 14.30 - Volume
668,791 - Avg. Volume
5,676,696 - Market Cap (intraday)
249.058M - Beta (5Y Monthly) -0.93
- PE Ratio (TTM)
-- - EPS (TTM)
-1.29 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
www.candeltx.comRecent News: CADL
Performance Overview: CADL
Trailing total returns as of 6/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CADL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CADL
Valuation Measures
Market Cap
264.83M
Enterprise Value
260.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
44.29
Enterprise Value/Revenue
821.98
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.54%
Return on Equity (ttm)
-163.77%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-37.37M
Diluted EPS (ttm)
-1.29
Balance Sheet and Cash Flow
Total Cash (mrq)
25.71M
Total Debt/Equity (mrq)
352.65%
Levered Free Cash Flow (ttm)
-19.24M
Research Analysis: CADL
Company Insights: CADL
CADL does not have Company Insights
Research Reports: CADL
Daily – Vickers Top Insider Picks for 03/08/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/07/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/06/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/03/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.